Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD

This study is testing a new drug called mirivadelgat in people who have pulmonary hypertension associated with interstitial lung disease (PH-ILD). This is a serious condition where high blood pressure develops in the lungs because of underlying scarring or inflammation of lung tissue. The drug targets a specific pathway to try to reduce pressure in the lungs and improve the ability to walk and breathe. **You may be eligible if...** - You are between 18 and 85 years old - You have been diagnosed with PH-ILD (confirmed by right heart catheterization and lung imaging) - You can walk between 100 and 500 meters in 6 minutes - Your lung function is reduced but not severely (specific FVC and DLCO thresholds) - You have been on stable treatment for your underlying lung disease for at least 30 days **You may NOT be eligible if...** - You have other types of pulmonary hypertension unrelated to lung disease - You have significant heart disease (weak heart, valve disease, or recent heart problems) - You are on other pulmonary hypertension-approved drugs (except inhaled treprostinil) - You have chronic kidney disease Stage IV or worse - You have used tobacco or marijuana within the last 6 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.